CD47, a bridge between innate and adaptive immunity, acts as the downstream effector molecule of the SMYD3 signal to promote the infiltration of T helper 2 (Th2) cells, protecting renal cancer cells from immune attack. Here, CD47 is linked to renal carcinoma.